Discovery of novel antigiardiasis drug candidates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7303-7311

  Kulakova, Liudmila ^a   Galkin, Andrey ^a   Chen, Catherine Z ^b   Southall, Noel ^b   Marugan, Juan J ^b   Zheng, Wei ^b   Herzberga, Osnat ^a,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Bldg 142   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 5 AZA 2' DEOXYCYTIDINE; ACIVICIN; AMLEXANOX; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIPROTOZOAL AGENT; AURANOFIN; BORTEZOMIB; CARBADOX; CARBOQUONE; CLAVULANIC ACID; DESERPIDINE; DISULFIRAM; FUMAGILLIN; HYDROXOCOBALAMIN; IDARUBICIN; METRONIDAZOLE; MITOXANTRONE; NIFUROXIME; NITARSONE; NITHIAMIDE; NOCODAZOLE; PICEATANNOL; RESVERATROL; RIBOFLAVIN BUTYRATE; RIBOFLAVIN DERIVATIVE; THIRAM; TIOXIDAZOLE; TRETAZICAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMINOPEPTIDASE; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN; METAP2 PROTEIN, HUMAN; METAP2 PROTEIN, MOUSE; SESQUITERPENE; THIAZOLE DERIVATIVE; UNSATURATED FATTY ACID;

ADULT; AMEBIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENCY; DRUG SCREENING; DRUG TREATMENT FAILURE; ENTEROCYTOZOON; EPITHELIUM CELL; FEMALE; GIARDIA LAMBLIA; GIARDIASIS; HIGH THROUGHPUT SCREENING; IC50; IN VITRO STUDY; MICROBIAL CONTAMINATION; MICROSPORIDIOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; TROPHOZOITE; ANIMAL; ANTAGONISTS AND INHIBITORS; AXENIC CULTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; DRUG SENSITIVITY; GIARDIA INTESTINALIS; GROWTH, DEVELOPMENT AND AGING; HUMAN; PARASITOLOGY; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

AMINOPEPTIDASES; ANIMALS; ANTIPROTOZOAL AGENTS; AXENIC CULTURE; CARBADOX; CYCLOHEXANES; DRUG DISCOVERY; DRUG RESISTANCE; FATTY ACIDS, UNSATURATED; GIARDIA LAMBLIA; GIARDIASIS; GLYCOPROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; METRONIDAZOLE; MICE; PARASITIC SENSITIVITY TESTS; SESQUITERPENES; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TROPHOZOITES;

EID: 84912127741     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03834-14     Document Type: Article

References (50)

1. Savioli L, Smith H, Thompson A. 2006. Giardia and Cryptosporidium join the 'Neglected Diseases Initiative.' Trends Parasitol. 22:203-208. http: //dx.doi.org/10.1016/j.pt.2006.02.015.
2. Cañete R, Escobedo AA, González ME, Almirall P, Cantelar N. 2006. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Curr. Med. Res. Opin. 22: 2131-2136. http://dx.doi.org/10 .1185/030079906X132497.
3. Escobedo AA, Alvarez G, González ME, Almirall P, Cañete R, Cimerman S, Ruiz A, Pérez R. 2008. The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide. Ann. Trop. Med. Parasitol. 102:199-207. http://dx.doi.org/10.1179/136485908X267894.
4. Lemée V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, Ballet JJ, Favennec L. 2000. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J. Antimicrob. Chemother. 46:819-821. http://dx.doi.org/10.1093/jac/46.5.819.
5. Upcroft P, Upcroft JA. 2001. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14:150-164. http://dx .doi.org/10.1128/CMR.14.1.150-164.2001.
6. Wensaas KA, Langeland N, Rortveit G. 2009. Prevalence of recurring symptoms after infection with Giardia lamblia in a non-endemic area. Scand. J. Prim. Health Care 27:12-17. http://dx.doi.org/10.1080 /02813430802602393.
7. Chen CZ, Kulakova L, Southall N, Marugan J, Galkin A, Austin C, Herzberg O, Zheng W. 2011. High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements. Antimicrob. Agents Chemother. 55: 667- 675. http://dx.doi.org/10.1128/AAC .00618-10.
8. Nash TE, McCutchan T, Keister D, Dame JB, Conrad JD, Gillin FD. 1985. Restriction-endonuclease analysis of DNA from 15 Giardia isolates obtained from humans and animals. J. Infect. Dis. 152:64-73. http://dx .doi.org/10.1093/infdis/152.1.64.
9. Keister DB. 1983. Axenic culture of Giardia lamblia in TYI-S-33 medium supplemented with bile. Trans. R. Soc. Trop. Med. Hyg. 77:487-488. http: //dx.doi.org/10.1016/0035-9203(83)90120-7.
10. Townson SM, Laqua H, Upcroft P, Boreham PF, Upcroft JA. 1992. Induction of metronidazole and furazolidone resistance in Giardia. Trans. R. Soc. Trop. Med. Hyg. 86:521-522. http://dx.doi.org/10.1016/0035 -9203(92)90095-T.
11. Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J, McKerrow JH, Reed SL, Eckmann L. 2013. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob. Agents Chemother. 57:2029-2035. http://dx.doi.org/10.1128 /AAC.01675-12.
12. Byrd LG, Conrad JT, Nash TE. 1994. Giardia lamblia infections in adult mice. Infect. Immun. 62:3583-3585.
13. Galkin A, Kulakova L, Lim K, Chen CZ, Zheng W, Turko IV, Herzberg O. 2014. Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. J. Biol. Chem. 289:10502-10509. http://dx.doi.org /10.1074/jbc.M114.553123.
14. Nash T, Rice WG. 1998. Efficacies of zinc-finger-active drugs against Giardia lamblia. Antimicrob. Agents Chemother. 42:1488-1492.
15. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. 1998. Dietary reference intakes: proposed definition and plan for review of dietary antioxidants and related compounds. The National Academies Press, Washington, DC.
16. Chen C, Southall N, Galkin A, Lim K, Marugan J, Kulakova L, Shinn P, van Leer D, Zheng W, Herzberg O. 2012. A homogenous luminescence assay reveals novel inhibitors for Giardia lamblia carbamate kinase. Curr. Chem. Genomics 6:93-102. http://dx.doi.org/10.2174/1875397301206010093.
17. Aggarwal A, Bhatia A, Naik SR, Vinayak VK. 1983. Variable virulence of isolates of Giardia lamblia in mice. Ann. Trop. Med. Parasitol. 77:163-167.
18. Hill DR, Guerrant RL, Pearson RD, Hewlett EL. 1983. Giardia lamblia infection of suckling mice. J. Infect. Dis. 147:217-221. http://dx.doi.org /10.1093/infdis/147.2.217.
19. Khanna R, Kum K, Vinayak VK. 1990. Gut-associated immune effector responses in immunocompetent and immunocompromised mice with Giardia lamblia. FEMS Microbiol. Immunol. 2:137-145.
20. Vinayak VK, Khanna R, Kum K. 1989. Sequential changes of lamina propria immunoglobulin-containing cells in immune intact and immunosuppressed mice infected with Giardia lamblia. Immunol. Cell Biol. 67:177-182.
21. Vinayak VK, Khanna R, Kum K, Nain CK. 1989. Functional characterization of intestinal intraepithelium & lamina propria lymphocytes from Giardia lamblia infected mice. Indian J. Med. Res. 89:271-281.
22. Killough JH, Magill GB, Smith RC. 1952. The treatment of amebiasis with fumagillin. Science 115:71-72. http://dx.doi.org/10.1126/science.115 .2977.71.
23. Molina JM, Tourneur M, Sarfati C, Chevret S, de Gouvello A, Gobert JG, Balkan S, Derouin F, Agence Nationale de Recherches sur le SIDA 090 Study Group. 2002. Fumagillin treatment of intestinal microsporidiosis. N. Engl. J. Med. 346: 1963-1969. http://dx.doi .org/10.1056/NEJMoa012924.
24. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661. http://dx.doi.org/10 .1096/fj.07-9574LSF.
25. Korzyoski T, Kowszyk GZ, Kurylowicz W. 1978. Antibiotics: origin, nature, and properties, vol 3. American Society for Microbiology, Washington, DC.
26. Gardner TB, Hill DR. 2001. Treatment of giardiasis. Clin. Microbiol. Rev. 14:114-128. http://dx.doi.org/10.1128/CMR.14.1.114-128.2001.
27. Champion L, Durrbach A, Lang P, Delahousse M, Chauvet C, Sarfati C, Glotz D, Molina JM. 2010. Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients. Am. J. Transplant. 10:1925-1930. http://dx.doi.org/10.1111/j.1600-6143.2010.03166.x.
28. Katznelson H, Jamieson CA. 1952. Control of nosema disease of honeybees with fumagillin. Science 115:70-71. http://dx.doi.org/10.1126 /science.115.2977.70.
29. Diesenhouse MC, Wilson LA, Corrent GF, Visvesvara GS, Grossniklaus HE, Bryan RT. 1993. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. Am. J. Ophthalmol. 115:293-298.
30. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557. http://dx.doi.org /10.1038/348555a0.
31. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J. 1991. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. 174:1070-1076. http://dx.doi.org/10.1016/0006-291X(91)91529-L.
32. Lijnen HR, Frederix L, Van Hoef B. 2010. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity (Silver Spring) 18:2241-2246. http://dx.doi.org/10.1038/oby.2009.503.
33. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. 2013. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring) 21:1782-1788. http://dx.doi.org/10.1002/oby.20356.
34. Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO. 2009. Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo. Chem. Biol. 16: 193-202. http://dx.doi.org/10.1016/j.chembiol.2009.01.006.
35. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. 1997. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. U. S. A. 94: 6099-6103. http://dx.doi.org/10.1073/pnas.94.12.6099.
36. Alvarado JJ, Nemkal A, Sauder JM, Russell M, Akiyoshi DE, Shi W, Almo SC, Weiss LM. 2009. Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470. Mol. Biochem. Parasitol. 168:158-167. http://dx.doi.org/10.1016/j.molbiopara .2009.07.008.
37. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. 1998. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282:1324-1327. http://dx.doi.org/10.1126/science.282.5392.1324.
38. Arfin SM, Kendall RL, Hall L, Weaver LH, Stewart AE, Matthews BW, Bradshaw RA. 1995. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc. Natl. Acad. Sci. U. S. A. 92:7714-7718. http://dx.doi.org/10.1073/pnas.92.17.7714.
39. Li X, Chang YH. 1995. Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc. Natl. Acad. Sci. U. S. A. 92:12357-12361. http://dx.doi.org/10.1073/pnas.92.26.12357.
40. Addlagatta A, Hu X, Liu JO, Matthews BW. 2005. Structural basis for the functional differences between type I and type II human methionine aminopeptidases. Biochemistry 44:14741-14749. http://dx.doi.org/10 .1021/bi051691k.
41. Bradshaw RA, Brickey WW, Walker KW. 1998. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem. Sci. 23: 263-267. http://dx.doi.org/10.1016 /S0968-0004(98)01227-4.
42. Kang JM, Ju HL, Sohn WM, Na BK. 2012. Characterization of the biochemical properties of two methionine aminopeptidases of Cryptosporidium parvum. Parasitol. Int. 61:707-710. http://dx.doi.org/10.1016/j .parint.2012.05.008.
43. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a Web-based environment for protein structure homology modelling. Bioinformatics 22:195-201. http://dx.doi.org/10.1093/bioinformatics /bti770.
44. Creusot F, Acs G, Christman JK. 1982. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2 = -deoxycytidine. J. Biol. Chem. 257: 2041-2048.
45. Varoqui H, Erickson JD. 1997. Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function. Mol. Neurobiol. 15:165-191.
46. Rao DN, Jordan S, Mason RP. 1988. Generation of nitro radical anions of some 5-nitrofurans, and 2- and 5-nitroimidazoles by rat hepatocytes. Biochem. Pharmacol. 37:2907-2913. http://dx.doi.org/10.1016/0006 -2952(88)90275-4.
47. Ralph SJ. 2008. Arsenic-based antineoplastic drugs and their mechanisms of action. Met. Based Drugs 2008:260146. http://dx.doi.org/10.1155/2008 /260146.
48. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG. 2007. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 51:868-876. http://dx.doi.org/10.1128/AAC.01159-06.
49. Geahlen RL, McLaughlin JL. 1989. Piceatannol (3,4,3=,5=-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 165:241-245. http://dx.doi.org/10 .1016/0006-291X(89)91060-7.
50. MacDonald LM, Armson A, Thompson AR, Reynoldson JA. 2004. Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol. Biochem. Parasitol. 138:89-96. http://dx.doi.org/10 .1016/j.molbiopara.2004.08.001.